Hypochromic red blood cells in low-risk myelodysplastic syndromes: Effects of treatment with hemopoietic growth factors

Haematologica

Volumn 89, Issue 12, 2004, Pages

  Ljung, Therese ^a   Bäck, Rune ^a   Hellström Lindberg, Eva ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Functional iron deficiency; Growth factors; Hypochromic erythrocytes; Myelodysplasia

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEMOPOIETIC GROWTH FACTOR;

ARTICLE; CELL MATURATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; ERYTHROBLAST; ERYTHROCYTE; ERYTHROCYTE COUNT; ERYTHROCYTE SCATTERGRAM; ERYTHROCYTE TRANSFUSION; ERYTHROCYTE VOLUME; FUNCTIONAL IRON DEFICIENCY; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; HYPOCHROMIC ERYTHROCYTE; HYPOCHROMIC RETICULOCYTE; INSTRUMENT; IRON DEFICIENCY; IRON STORAGE; MEAN CORPUSCULAR VOLUME; MYELODYSPLASTIC SYNDROME; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; RETICULOCYTE; RETICULOCYTE COUNT;

ANEMIA, REFRACTORY; ANEMIA, SIDEROBLASTIC; BLOOD CELL COUNT; DRUG THERAPY, COMBINATION; ERYTHROCYTE INDICES; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; ERYTHROPOIETIN; FERRITINS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMOGLOBINS; HUMANS; IRON; METHYLMALONIC ACID; RETICULOCYTES; RISK; TRANSFERRIN;

EID: 19744364850     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Aul C, Bowen D, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998;83:71-86.
2. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposal for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
3. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
4. Cazzola M, Invernizzi R, Bergamaschi G, Levi S, Corsi B, Travaglino E, et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 2003;101:1996-2000.
5. van de Loosdrecht AA, Brada SJ, Blom NR, Hendriks DW, Smit JW, van den Berg E, et al. Mitochondrial disruption and limited apoptosis of erythroblasts are associated with high risk myelodysplasia. An ultrastructural analysis. Leuk Res 2001;25:385-93.
6. Bowen D, Williams K, Phillips I, Cavill I. Cytometric analysis and maturation characteristics of reticulocytes from myelodysplastic patients. Clin Lab Haematol 1996;18:155-60.
7. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998;92:68-75.
8. Hellstrom-Lindberg E. Approach to anemia associated with myelodysplastic syndromes. Curr Hematol Rep 2003; 2: 122-9.
9. Hast R, Wallvik J, Polin A, Berneil P, Stenke L. Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment. Leuk Res 2001; 25:13-8.
10. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002;48:1066-76.
11. Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, et al. The role of iron status markers in predicting response to intravenous iron in haemodialytic patients on maintenance erythropoietin. Nephrol Dial Transplant 2001;16:1416-23.
12. Musto P, Modoni S, Alicino G, Savino A, Longo A, Bodenizza C, et al. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes. Haematologica 1994;79:493-9.
13. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100:2303-20.
14. Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, et al. UK MDS Guidelines Group. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003; 120: 187-200.
15. Kotisaari S, Romppanen J, Penttila I, Punnonen K. The Advia 120 red blood cells and reticulocyte indices are useful in diagnosis of iron-deficiency anemia. Eur J Haematol 2002;3:150-6.
16. Brugnara C, Laufer MR, Friedman AJ, Bridges K, Platt O. Reticulocyte hemoglobin content (CHr): an early indictor of iron deficiency and response to therapy. Blood 1994;83:3100-1.
17. Rasmussen, K. Solid phase sample extraction for rapid determination of methylmalonic acid in serum and urine by a stabile-isotope-dilutiuon method. Clin Chem 1989;35:260-4.
18. Mast AE, Blinder MA, Lu Q, Flax S, Dietzen DJ. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood 2002; 99: 1489-91.
19. Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res 1997; 21:415-25.
20. Tehranchi R, Fadeel B, Forsblom AM, Christensson B, Samuelsson J, Zhivotovsky B, et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 2003;101:1080-6.
21. Nilsson L, Astrand-Grundstrom I, Arvidsson I, Jacobsson B, Hellstrom-Lindberg E, Hast R, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000;96:2012-21.
22. Rigolin GM, Porta MD, Bigoni R, Cavazzini F, Ciccone M, Bardi A, Cuneo A, et al. rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples. Br J Haematol 2002;119:652-9.